MTSL Issue 850

 Comments Off on MTSL Issue 850
Apr 232017
 
MTSL Issue 850

MTSL Issue 850 (dated 4/20/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #IONS #INCY #MDGL #NKTR #ZIOP

MTSL Issue 849

 Comments Off on MTSL Issue 849
Apr 022017
 
MTSL Issue 849

MTSL Issue 849 (dated 3/30/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #ANTH #ESPR #IONS #NKTR #SGMO #ZIOP

Nektar (NKTR) 02-20-17

 Comments Off on Nektar (NKTR) 02-20-17
Mar 232017
 
Nektar (NKTR) 02-20-17

BIOINVEST BREAKING NEWS – Nektar (NKTR) – NKTR-181 Successful In Phase III SUMMIT-07 Trial & Sets The Stage For A Revolution In Pain Drugs – Raising BUY and TARGET PRICE

The SUMMIT-07 trial met its primary endpoint demonstrating highly significant improved chronic back pain relief with NKTR-181 compared to placebo (p=0.0019). Moreover, the safety and tolerability of ‘181 in SUMMIT supports its breakthrough profile for moderate-to-severe pain relief without the abuse and addiction that has caused the opioid epidemic of today

MTSL Issue 847

 Comments Off on MTSL Issue 847
Mar 052017
 
MTSL Issue 847

MTSL Issue 847 (dated 3/02/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #BMRN #CELG #FPRX #INCY #XON #IONS #MDCO #NKTR #PCRX #SGMO

MTSL Issue 844

 Comments Off on MTSL Issue 844
Jan 222017
 
MTSL Issue 844

MTSL Issue 844 (dated 1/19/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #BMRN #CELG #INCY #IONS #MDCO #NKTR #PCRX #SGMO #ZIOP

MTSL Issue 837

 Comments Off on MTSL Issue 837
Oct 092016
 
MTSL Issue 837

MTSL Issue 837 (10/06/16) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #INCY #IONS #MDCO #NKTR #XON

MTSL Issue 833

 Comments Off on MTSL Issue 833
Aug 142016
 
MTSL Issue 833

MTSL Issue 833 (dated 8/11/16) of Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis & updates from these companies: #ACAD #ANTH #BMRN #FPRX #INCY #XON #IONS #MDCO #NKTR #NVAX #PCRX #SGMO #ZIOP

MTSL Issue 827

 Comments Off on MTSL Issue 827
May 152016
 
MTSL Issue 827

MTSL Issue 827 (dated 5/12/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ACAD #ANTH #FPRX #INCY #IONS #XON #MDCO #NKTR #NVAX #PCRX #ZIOP

MTSL Issue 826

 Comments Off on MTSL Issue 826
May 012016
 
MTSL Issue 826

MTSL Issue 826 (dated 4/28/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ALKS #BMRN #FPRX #INCY #IONS #NKTR #XON #ZIOP

MTSL Issue 817

 Comments Off on MTSL Issue 817
Dec 202015
 
MTSL Issue 817

Issue No. 817 (dated 12/17/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH #ALKS #MDCO #NKTR #NVAX #OGXI #PCRX SGMO #ZIOP

MTSL Issue 816

 Comments Off on MTSL Issue 816
Dec 062015
 
MTSL Issue 816

Issue No. 816 (dated 12/3/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #BMRN #XON #MDCO #NKTR #NVAX #OGXI #SGMO #ZIOP

MTSL Issue 815

 Comments Off on MTSL Issue 815
Nov 152015
 
MTSL Issue 815

Issue No. 815 (dated 11/12/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH, #ACAD, #FPRX, #INCY, #ISIS, #MDCO, #NKTR, #NVAX, #OGXI, #XON

Nektar Update (9-26-13)

 Comments Off on Nektar Update (9-26-13)
Sep 272013
 
Nektar Update (9-26-13)

Nektar’s NKTR-181 Disappoints, Misses Primary Endpoint on Mixed Phase II Data – Preliminary top-line results from a Phase II trial of NKTR-181(‘181) for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis of the knee missed their primary endpoint due to a unusual lack of a placebo rebound.  The drug candidate was shown to […]

Nektar Update (1-18-13)

 Comments Off on Nektar Update (1-18-13)
Jan 182013
 
Nektar Update (1-18-13)

CONTINUED PROGRESS AND PIPELINE VISIBILITY. Nektar management continues to make progress across its late–stage development pipeline, relieving some investor concern for the naloxegol (NKTR-118) program – NKTR’s lead compound – under development for the treatment of opioid-induced constipation (OIC).  With renewed optimism on the ‘118 program and upcoming related catalysts, increasing appreciation of the breadth […]

Nektar Update (11-16-12)

 Comments Off on Nektar Update (11-16-12)
Nov 162012
 
Nektar Update (11-16-12)

Nektar’s stock has had a horrible two weeks despite announcing positive top-line results from two Phase III trials and one safety extension trial in patients with non-cancer related pain and opioid-induced constipation (OIC). Last week, potential FDA concerns with CV risk associated with opioid withdrawal in chronic use of opioid antagonists became an investor issue […]